Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.
Identifieur interne : 001916 ( PubMed/Checkpoint ); précédent : 001915; suivant : 001917Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.
Auteurs : Didier Musso [Polynésie française]Source :
- Pathogens and global health [ 2047-7732 ] ; 2013.
Descripteurs français
- KwdFr :
- Albendazole (usage thérapeutique), Analyse coût-bénéfice, Animaux, Antigènes d'helminthe (sang), Antihelminthiques (usage thérapeutique), Brugia malayi (isolement et purification), Dépistage systématique, Femelle, Filariose lymphatique (sang), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Granulocytes éosinophiles, Humains, Mâle, Organisation mondiale de la santé, Polynésie (épidémiologie), Processus politique, Prévalence, Surveillance de la population, Tests diagnostiques courants (économie), Valeur prédictive des tests, Wuchereria bancrofti (isolement et purification).
- MESH :
- isolement et purification : Brugia malayi, Wuchereria bancrofti.
- sang : Antigènes d'helminthe, Filariose lymphatique.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Antihelminthiques.
- économie : Tests diagnostiques courants.
- épidémiologie : Filariose lymphatique, Polynésie.
- Analyse coût-bénéfice, Animaux, Dépistage systématique, Femelle, Granulocytes éosinophiles, Humains, Mâle, Organisation mondiale de la santé, Processus politique, Prévalence, Surveillance de la population, Valeur prédictive des tests.
English descriptors
- KwdEn :
- Albendazole (therapeutic use), Animals, Anthelmintics (therapeutic use), Antigens, Helminth (blood), Brugia malayi (isolation & purification), Cost-Benefit Analysis, Diagnostic Tests, Routine (economics), Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Eosinophils, Female, Humans, Male, Mass Screening, Policy Making, Polynesia (epidemiology), Population Surveillance, Predictive Value of Tests, Prevalence, World Health Organization, Wuchereria bancrofti (isolation & purification).
- MESH :
- chemical , blood : Antigens, Helminth.
- chemical , therapeutic use : Albendazole, Anthelmintics.
- geographic , epidemiology : Polynesia.
- blood : Elephantiasis, Filarial.
- drug therapy : Elephantiasis, Filarial.
- economics : Diagnostic Tests, Routine.
- epidemiology : Elephantiasis, Filarial.
- isolation & purification : Brugia malayi, Wuchereria bancrofti.
- Animals, Cost-Benefit Analysis, Eosinophils, Female, Humans, Male, Mass Screening, Policy Making, Population Surveillance, Predictive Value of Tests, Prevalence, World Health Organization.
Abstract
Lymphatic filariasis constitutes a major public health issue in French Polynesia. Diagnosis has been revolutionized with the availability of circulating filarial antigen (CFA) tests which are easy to perform but are costly. Filariasis is responsible for acquired eosinophilia and eosinophil blood count (EBC) is commonly used as a screening tool.
DOI: 10.1179/2047773213Y.0000000083
PubMed: 23683336
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23683336Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.</title><author><name sortKey="Musso, Didier" sort="Musso, Didier" uniqKey="Musso D" first="Didier" last="Musso">Didier Musso</name><affiliation wicri:level="1"><nlm:affiliation>Emerging Infectious Disease Unit, Institut Louis Malardé, Tahiti, French Polynesia. dmusso@ilm.pf</nlm:affiliation><country xml:lang="fr">Polynésie française</country><wicri:regionArea>Emerging Infectious Disease Unit, Institut Louis Malardé, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23683336</idno><idno type="pmid">23683336</idno><idno type="doi">10.1179/2047773213Y.0000000083</idno><idno type="wicri:Area/PubMed/Corpus">001B48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B48</idno><idno type="wicri:Area/PubMed/Curation">001B48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B48</idno><idno type="wicri:Area/PubMed/Checkpoint">001B48</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.</title><author><name sortKey="Musso, Didier" sort="Musso, Didier" uniqKey="Musso D" first="Didier" last="Musso">Didier Musso</name><affiliation wicri:level="1"><nlm:affiliation>Emerging Infectious Disease Unit, Institut Louis Malardé, Tahiti, French Polynesia. dmusso@ilm.pf</nlm:affiliation><country xml:lang="fr">Polynésie française</country><wicri:regionArea>Emerging Infectious Disease Unit, Institut Louis Malardé, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author></analytic><series><title level="j">Pathogens and global health</title><idno type="eISSN">2047-7732</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Anthelmintics (therapeutic use)</term><term>Antigens, Helminth (blood)</term><term>Brugia malayi (isolation & purification)</term><term>Cost-Benefit Analysis</term><term>Diagnostic Tests, Routine (economics)</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Eosinophils</term><term>Female</term><term>Humans</term><term>Male</term><term>Mass Screening</term><term>Policy Making</term><term>Polynesia (epidemiology)</term><term>Population Surveillance</term><term>Predictive Value of Tests</term><term>Prevalence</term><term>World Health Organization</term><term>Wuchereria bancrofti (isolation & purification)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (usage thérapeutique)</term><term>Analyse coût-bénéfice</term><term>Animaux</term><term>Antigènes d'helminthe (sang)</term><term>Antihelminthiques (usage thérapeutique)</term><term>Brugia malayi (isolement et purification)</term><term>Dépistage systématique</term><term>Femelle</term><term>Filariose lymphatique (sang)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Granulocytes éosinophiles</term><term>Humains</term><term>Mâle</term><term>Organisation mondiale de la santé</term><term>Polynésie (épidémiologie)</term><term>Processus politique</term><term>Prévalence</term><term>Surveillance de la population</term><term>Tests diagnostiques courants (économie)</term><term>Valeur prédictive des tests</term><term>Wuchereria bancrofti (isolement et purification)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antigens, Helminth</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Anthelmintics</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Polynesia</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Diagnostic Tests, Routine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Brugia malayi</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Brugia malayi</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes d'helminthe</term><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Antihelminthiques</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Tests diagnostiques courants</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Polynésie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cost-Benefit Analysis</term><term>Eosinophils</term><term>Female</term><term>Humans</term><term>Male</term><term>Mass Screening</term><term>Policy Making</term><term>Population Surveillance</term><term>Predictive Value of Tests</term><term>Prevalence</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Animaux</term><term>Dépistage systématique</term><term>Femelle</term><term>Granulocytes éosinophiles</term><term>Humains</term><term>Mâle</term><term>Organisation mondiale de la santé</term><term>Processus politique</term><term>Prévalence</term><term>Surveillance de la population</term><term>Valeur prédictive des tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphatic filariasis constitutes a major public health issue in French Polynesia. Diagnosis has been revolutionized with the availability of circulating filarial antigen (CFA) tests which are easy to perform but are costly. Filariasis is responsible for acquired eosinophilia and eosinophil blood count (EBC) is commonly used as a screening tool.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23683336</PMID><DateCreated><Year>2013</Year><Month>05</Month><Day>20</Day></DateCreated><DateCompleted><Year>2013</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2047-7732</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Pathogens and global health</Title><ISOAbbreviation>Pathog Glob Health</ISOAbbreviation></Journal><ArticleTitle>Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.</ArticleTitle><Pagination><MedlinePgn>96-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1179/2047773213Y.0000000083</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lymphatic filariasis constitutes a major public health issue in French Polynesia. Diagnosis has been revolutionized with the availability of circulating filarial antigen (CFA) tests which are easy to perform but are costly. Filariasis is responsible for acquired eosinophilia and eosinophil blood count (EBC) is commonly used as a screening tool.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analysed all the results of EBCs and CFA tests performed in our laboratory over a 2-year period. We calculated the prevalence of antigenemia for nine different eosinophil cutoffs. We calculated the number of patients detected by CFA testing and the number of estimated CFA-positive patients according to their EBC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over a 2-year period, we detected 7503 eosinophilic patients. For an EBC above 500/mm(3), the prevalence of positive CFA was 25·78% and the estimated number of positive CFA patients was 1934. During the same period, as CFA determination is not routinely performed, only 141 patients were detected and treated.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our current strategy against lymphatic filariasis which combines annual mass drug administration, systematic treatment of antigenemic and microfilaraemic patients, and vector control; failed to reach the target of 1% prevalence. Unfortunately, mainly for economical reasons, the antigenemia cannot be determined for all patients. In complement to existing strategy, we propose an additional action based on the treatment of eosinophilic patients in order to reduce the filariasis prevalence in our country.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Musso</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Emerging Infectious Disease Unit, Institut Louis Malardé, Tahiti, French Polynesia. dmusso@ilm.pf</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pathog Glob Health</MedlineTA><NlmUniqueID>101583421</NlmUniqueID><ISSNLinking>2047-7724</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000871">Anthelmintics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Indian J Med Res. 2007 Dec;126(6):567-74</RefSource><PMID Version="1">18219085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Parasitol. 1994 Sep;45(3):255-7</RefSource><PMID Version="1">7899800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2012 Jan;6(1):e1479</RefSource><PMID Version="1">22272369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Allergy Clin Immunol. 2010 Jul;126(1):39-44</RefSource><PMID Version="1">20538328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1987 May 1;138(9):3035-41</RefSource><PMID Version="1">3553330</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mayo Clin Proc. 2005 Jan;80(1):75-83</RefSource><PMID Version="1">15667033</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Trop Med Parasitol. 2002 Dec;96 Suppl 2:S143-52</RefSource><PMID Version="1">12625927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 1996 Sep;55(3):333-7</RefSource><PMID Version="1">8842125</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Oct 1;49(7):1103-8</RefSource><PMID Version="1">19691431</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasit Vectors. 2010 Oct 20;3:100</RefSource><PMID Version="1">20961435</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 1996 Dec;1(6):859-64</RefSource><PMID Version="1">8980602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2004 Nov;9(11):1200-2</RefSource><PMID Version="1">15548316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Trop Med. 2011;2011:175941</RefSource><PMID Version="1">21234244</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasitol Today. 1997 Oct;13(10):401-4</RefSource><PMID Version="1">15275155</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parasite. 1999 Dec;6(4):355-8</RefSource><PMID Version="1">10633507</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Biomed. 2008 Aug;79(2):106-9</RefSource><PMID Version="1">18788504</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2007 Jan;23(1):36-40</RefSource><PMID Version="1">17126604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2006 May;74(5):826-32</RefSource><PMID Version="1">16687688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 1989 Jan;2(1):39-50</RefSource><PMID Version="1">2644023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Trop Med Hyg. 2008 Jan;78(1):28-34</RefSource><PMID Version="1">18187781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Asian Pac J Allergy Immunol. 2003 Dec;21(4):253-7</RefSource><PMID Version="1">15198343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Allergy Clin North Am. 2007 Aug;27(3):529-49</RefSource><PMID Version="1">17868863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Filaria J. 2006 Aug 16;5:10</RefSource><PMID Version="1">16914040</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000871" MajorTopicYN="N">Anthelmintics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017178" MajorTopicYN="N">Brugia malayi</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003955" MajorTopicYN="N">Diagnostic Tests, Routine</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004804" MajorTopicYN="Y">Eosinophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011050" MajorTopicYN="N">Policy Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011114" MajorTopicYN="N" Type="Geographic">Polynesia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4001484</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23683336</ArticleId><ArticleId IdType="doi">10.1179/2047773213Y.0000000083</ArticleId><ArticleId IdType="pmc">PMC4001484</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Polynésie française</li></country></list><tree><country name="Polynésie française"><noRegion><name sortKey="Musso, Didier" sort="Musso, Didier" uniqKey="Musso D" first="Didier" last="Musso">Didier Musso</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001916 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001916 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23683336
|texte= Relevance of the eosinophil blood count in bancroftian filariasis as a screening tool for the treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23683336" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |